Australia's most trusted
source of pharma news
Posted 24 September 2021 AM
Covid therapies developed by MSD and Roche are among seven new medicines that have been accepted for review by the TGA this month.
The regulator revealed it is currently reviewing Roche's antibody cocktail Ronapreve and MSD's oral antiviral molnupiravir with its local brand name still "to be confirmed" via the provisional approval pathway.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.